Scaling Up Diarrhea Prevention and Treatment Interventions: A Lives Saved
Tool Analysis
Background:
Diarrhea remains a leading cause of mortality among young children in low- and
middle-income countries. Although the evidence for individual diarrhea prevention
and treatment interventions is solid, the effect a comprehensive scale-up effort
would have on diarrhea mortality has not been estimated.
Methods and Findings:
We use the Lives Saved Tool (LiST) to estimate the potential
lives saved if two scale-up scenarios for key diarrhea interventions (oral
rehydration salts [ORS], zinc, antibiotics for dysentery, rotavirus
vaccine, vitamin A supplementation, basic water, sanitation, hygiene, and
breastfeeding) were implemented in the 68 high child mortality countries. We also
conduct a simple costing exercise to estimate cost per capita and total costs for
each scale-up scenario. Under the ambitious (feasible improvement in coverage of
all interventions) and universal (assumes near 100% coverage of all
interventions) scale-up scenarios, we demonstrate that diarrhea mortality can be
reduced by 78% and 92%, respectively. With universal coverage nearly
5 million diarrheal deaths could be averted during the 5-year scale-up period for
an additional cost of US$12.5 billion invested across 68 priority countries
for individual-level prevention and treatment interventions, and an additional
US$84.8 billion would be required for the addition of all water and
sanitation interventions.
Conclusion:
Using currently available interventions, we demonstrate that with improved
coverage, diarrheal deaths can be drastically reduced. If delivery strategy
bottlenecks can be overcome and the international community can collectively
deliver on the key strategies outlined in these scenarios, we will be one step
closer to achieving success for the United Nations' Millennium Development
Goal 4 (MDG4) by 2015.
:
Please see later in the article for the Editors' Summary
Published in the journal:
. PLoS Med 8(3): e32767. doi:10.1371/journal.pmed.1000428
Category:
Research Article
doi:
https://doi.org/10.1371/journal.pmed.1000428
Summary
Background:
Diarrhea remains a leading cause of mortality among young children in low- and
middle-income countries. Although the evidence for individual diarrhea prevention
and treatment interventions is solid, the effect a comprehensive scale-up effort
would have on diarrhea mortality has not been estimated.
Methods and Findings:
We use the Lives Saved Tool (LiST) to estimate the potential
lives saved if two scale-up scenarios for key diarrhea interventions (oral
rehydration salts [ORS], zinc, antibiotics for dysentery, rotavirus
vaccine, vitamin A supplementation, basic water, sanitation, hygiene, and
breastfeeding) were implemented in the 68 high child mortality countries. We also
conduct a simple costing exercise to estimate cost per capita and total costs for
each scale-up scenario. Under the ambitious (feasible improvement in coverage of
all interventions) and universal (assumes near 100% coverage of all
interventions) scale-up scenarios, we demonstrate that diarrhea mortality can be
reduced by 78% and 92%, respectively. With universal coverage nearly
5 million diarrheal deaths could be averted during the 5-year scale-up period for
an additional cost of US$12.5 billion invested across 68 priority countries
for individual-level prevention and treatment interventions, and an additional
US$84.8 billion would be required for the addition of all water and
sanitation interventions.
Conclusion:
Using currently available interventions, we demonstrate that with improved
coverage, diarrheal deaths can be drastically reduced. If delivery strategy
bottlenecks can be overcome and the international community can collectively
deliver on the key strategies outlined in these scenarios, we will be one step
closer to achieving success for the United Nations' Millennium Development
Goal 4 (MDG4) by 2015.
:
Please see later in the article for the Editors' Summary
Introduction
Diarrhea remains a leading cause of morbidity and mortality among children under 5 y of age in low- and middle-income countries [1]. Diarrhea mortality has declined from an estimated 4.5 million deaths in the early 1980s to 1.3 million in 2008 with the advent of oral rehydration salts (ORS), the implementation of routine vitamin A supplementation and measles vaccine, improved sanitation, access to clean water, and hand washing, which are major risk factors for diarrhea incidence in many parts of the world [1],[2]. Given the availability of cost-effective prevention and treatment interventions, however, the number of deaths owing to diarrhea remains unacceptably high. Further reduction of diarrhea mortality is critical if the fourth United Nations' Millennium Development Goal (MDG4) —reduction of child mortality by two-thirds of the 1990 level (12.4 million deaths per year) — is to be achieved by 2015.
In 2009, UNICEF and WHO published a report on diarrhea that included a package of key diarrhea prevention and treatment interventions to reduce diarrhea morbidity and mortality. The complete package includes improving access to safe water, community-wide promotion of sanitation, routine rotavirus and measles immunization, vitamin A supplementation and promotion of breastfeeding, and treatment with ORS and zinc [3]. Although the full package of prevention and treatment interventions is based on solid evidence supporting individual interventions, the effect that a universal scale-up effort would have on diarrhea mortality has not been estimated.
The Lives Saved Tool (LiST) is designed to enable international agencies and country planners to estimate the effect of increasing coverage of selected intervention combinations, such as the UNICEF/WHO recommended interventions for diarrhea, on mortality. LiST utilizes country-specific cause of death profiles and the effect of selected interventions on cause-specific mortality, and thus generates country-specific estimates of mortality reductions [4].
Here, we present two scenarios for the scale-up of diarrhea prevention and treatment interventions from 2010 to 2015. We use LiST to estimate the potential lives saved if each scale-up scenario were implemented in the 68 “Countdown to 2015” countries. These 68 countries were prioritized by UNICEF and partners on the basis of high child mortality rates; together they represent more than 95% of child deaths [5]. These data are critical for program planners, funders, and policy and decision makers to better understand the potential impact on mortality when investing in diarrhea prevention and treatment at the country level.
Methods
LiST is a child survival modeling tool that uses country level under-5 mortality rates and cause of death profiles, and models the effects of changes in coverage of interventions on overall and cause-specific mortality rates for children under 5 y of age (http://www.jhsph.edu/dept/ih/IIP/list/spectrum.html) [4],[6]. It is built into the Spectrum policy modeling system, which includes a demographic platform based on UN population data, HIV, and family planning inputs. As a public access tool, analyses such as these can be performed, repeated, or altered by researchers or program and policy leaders alike. The effectiveness of each of the diarrhea interventions incorporated into the LiST tool has been recently reviewed by the Child Health Epidemiology Reference Group (CHERG) [7]–[11] and as part of a universal and published review [12],[13]. The CHERG reviews go beyond previously published systematic reviews and meta-analyses, utilizing all available data to provide the best estimate for the effect of each intervention on diarrhea-specific mortality [6]. In previous exercises, the LiST tool has estimated mortality reductions due to coverage changes that have matched well to the measured changes in mortality [14],[15].
Establishing Baseline Values for Cause of Death and Coverage of Interventions
For this exercise, we generated LiST models for each of the 68 priority countries to project potential reductions in diarrhea mortality [5]. We used standard country-level child mortality rates as published by the Interagency Group for Child Mortality Estimation and the cause of death profiles published by the CHERG [16],[17]. We used baseline intervention coverage values for improved water supply, household connection, and improved sanitation from a special analysis of WHO/UNICEF Joint Monitoring Programme for Water Supply and Sanitation (JMP) data [18]. For these interventions we assumed no change in coverage between most recent available data points (typically 2008) and 2010. Vaccination and vitamin A coverage levels were based on WHO/UNICEF immunization program data [19]. All other baseline intervention coverage data were based on the most recent Demographic Health Survey (DHS), Multiple Indicator Cluster Survey (MICS), or Malaria Indicator Survey (MIS). Coverage data were not available for selected indicators in Papua New Guinea and Democratic People's Republic of Korea; for the former, we used estimated average regional data for Southeast Asia for ORS and antibiotic use, and for the latter, estimated data from China were used for breastfeeding and antibiotic use (see Table S1 for values).
Ten interventions proven to reduce diarrheal mortality were modeled. The preventive interventions were breastfeeding, vitamin A supplementation, hand washing with soap, improved sanitation (which encompasses toilet facilities and disposal of waste), improved drinking-water source, treatment of water in the home, and rotavirus vaccination. The treatment interventions included were ORS and zinc as well as antibiotics for dysentery. To model “treatment of water in the home,” we assumed a value of 0.21 for the effect of this indicator on diarrhea incidence and mortality [20]. Current coverage of this indicator is not available for all countries and it would be inappropriate to assume that 100% of households currently need clean water. We used the percent of children living in households with piped water as a proxy for current coverage of a clean water supply, available for all countries from the JMP [18]. This is likely to generate a conservative estimate of the potential impact of treatment of water, as it is probable that some households with piped water also need treatment. We included antibiotics for dysentery, though this was not included in the recent UNICEF/WHO recommended package, because it remains an important tool for treating dysenteric diarrhea. Lastly, measles vaccination, which is included in the UNICEF/WHO recommended package, was not included because measles-related diarrheal deaths are attributed to measles directly. Baseline values are presented in Table 1 for all interventions except breastfeeding. Additional details with regard to assumptions about breastfeeding coverage can be found in Table S1.
Modeling Increased Coverage of Interventions
Within the model, all chosen interventions have a direct impact on diarrheal mortality reduction. Four of the seven interventions—improved water source, treatment of water in the home, hand washing with soap, and improved sanitation—also have an indirect impact on multiple causes of mortality via a reduction in the rate of stunting. LiST applies the documented effectiveness for each intervention to the total diarrheal deaths possible among children under 5 for each given year. For each intervention the effectiveness value is applied to the residual number of diarrheal deaths available to “save” for that year thus eliminating the potential to double count lives saved.
The scale-up scenarios presented here assume a linear increase in coverage from the baseline coverage year, 2010 (using the most recent data available) through the year 2015; this allowed us to generate the total number of diarrheal deaths, by country for each year between 2010 and 2015. For an estimate of baseline diarrheal deaths we applied the 2008 overall mortality rate and the cause of death structure to the 2010 population.
We applied two different scale-up scenarios of the seven diarrhea prevention and three treatment interventions, representing ambitious but feasible coverage objectives and a universal coverage plan. The first or “ambitious” scenario represents what is felt to be an essential and realizable scale-up strategy as countries strive to reduce under-five mortality in the context of achievement of MDG4, whereas the second or “universal” scenario represents maximum levels that could be achieved through an aggressive, highly concerted, and better-funded initiative. Table 2 shows the coverage levels used in the analysis, representing the ambitious and universal scale-up scenarios. For breastfeeding, coverage estimates vary by age group (<1 mo, 1–5 mo, 6–11 mo, 12–23 mo) and degree of exclusivity (exclusive, predominant, partial, none). For any country that has already attained the modeled level of coverage for a specific intervention, we assumed maintenance of the achieved coverage rate. Additional details on individual country calculations can be found in Table S1.
Estimating the Cost of Scale-up
We conducted a cost analysis for the specified interventions in both scale-up scenarios using an ingredients-based approach. For preventive interventions the population in need was defined as the number of children under 5 (vitamin A, rotavirus vaccine, breastfeeding) or, for the water, sanitation, and hygiene (WASH) interventions, the households with children under 5 y. For the treatment interventions we assumed that all cases would receive ORS and zinc; we also estimated the proportion of episodes that would meet the clinical definition of dysentery and require antibiotic treatment. Drug, supply and personnel time requirements per average case were calculated based on WHO treatment guidelines and expert opinion, and then costed using UNICEF's supply catalogue [21] and WHO CHOICE's country-specific database of medical staff salaries [22]. We also included costs of outreach activities and communication strategies. For non-WASH interventions, the analysis looked only at direct costs of providing the interventions; costs associated with capital investments such as building new health centers and training facilities are not captured in this analysis. We calculated the costs for the continuation of baseline coverage rates and the scale-up of both scenarios for all 68 countries included in this model. We then calculated the total per capita (total population) cost as well as the additional per capita cost to achieve each final coverage target for each year through 2015. Costs for the WASH interventions were kept separate from the individual-level prevention and treatment interventions.
Results
Figure 1 presents trends in the number of diarrheal deaths between 2010 and 2015 for each of the two scenarios; it also shows the proportion of diarrheal deaths that would occur each year relative to the 2010 baseline values. Under the ambitious scenario, the number of diarrheal deaths would decline from more than 1.39 million a year in the baseline year of 2010 to 334,000 in 2015, which represents a 78% decline and nearly 1 million deaths averted in 2015. Over the 5-y scale-up period, more than 3.8 million deaths would be averted. Assuming linear scale-up, the estimated additional cost to achieve this reduction is US$0.49 per capita in 2015 for the non-WASH interventions and an additional US$1.78 per capita if 100% of the cost of the WASH interventions was to be borne by the public health system (Table 3). The total additional cost for scaling up all non-WASH interventions as per the ambitious scenario in these 68 countries over a 5-y period is US$7.7 billion. If WASH interventions were to be included the costs would rise to US$49.2 billion.
With the universal coverage scenario, the number of diarrheal deaths would drop to less than 115,000 in 2015, more than a 92% decline from the 2010 levels, representing nearly 1.4 million deaths averted in 2015 (Figures 1 and 2) and more than 4.9 million deaths during the 5-y scale-up period. To achieve these coverage rates, we estimate an additional cost of US$0.80 per capita in 2015 and an additional US$3.24 per capita with the addition of all WASH interventions at the highest coverage rates and all costs borne by the health system (Table 2). The total additional cost for scaling up all non-WASH interventions, as per the universal scenario in the 68 countries included in these analyses over a 5-y period, is US$12.5 billion. If WASH interventions are also included the costs rise to US$84.8 billion. Under both scenarios, 51% of deaths averted would be in just five countries: India, Nigeria, Democratic Republic of the Congo, Pakistan, and Afghanistan, that is 700,000 and 900,000 deaths in 2015 in the ambitious and universal scale-up scenarios, respectively.
Discussion
In this exercise we used LiST to simulate the potential lives that could be saved by scaling-up ten simple and effective interventions for the prevention and treatment of diarrhea in 68 priority countries. The results of this modeling exercise demonstrate that with currently available technology, diarrheal deaths could be reduced by at least 78% by the end of 2015. To reach MDG4 by 2015, the number of child deaths needs to be reduced by an additional 4.6 million annually from the 2008 estimate of 8.8 million. Reducing diarrheal deaths by more than 1.4 million per year would be a major contribution toward this goal.
By using LiST to model the impact of scaling up multiple interventions we are able to illustrate the potential benefits of two scale-up scenarios over a 5-y period. LiST is a useful tool for modeling the effect of multiple prevention and treatment interventions because the effect of each intervention is applied step-wise in a cohort model. With this type of model, the effect of a second intervention is only observed on the residual of the first intervention. This ensures that potential lives are not saved more than once thus eliminating the risk of double counting. While coverage for many interventions, such as ORS, is routinely collected in most countries, coverage data for water and sanitation interventions that truly reflect optimal practices are extremely limited and in the case of home purification of water, completely missing for many countries. Thus, as coverage data improve, estimates generated by LiST will continue to improve.
In this exercise we did not account for the fact that a proportion of children will have access to all interventions, while a proportion of children representing those hardest to reach will likely receive few, if any, of the interventions [23]. The LiST tool assumes linearity between coverage of the intervention and the lives saved. Though we recognize that this may not be an accurate portrayal of what happens as coverage increases within a community, we do not currently have the evidence to support an alternative such as a threshold effect, minimum coverage, or herd immunity for these interventions. Ensuring that these lifesaving diarrhea prevention and treatment interventions reach the poorest and most vulnerable populations will be crucial for achievement of equity and maximum impact when scaling up programs if the predicted mortality reductions are to be achieved. For this model, the baseline scenario assumes current coverage values would remain the same through 2015 and thus diarrhea mortality rates would also remain constant. We recognize that there might be some small change in diarrhea mortality as a result of improved economic conditions, and other factors within a community which could also impact diarrhea mortality and are not captured here, but we believe these changes would be relatively small over the short time period captured in this exercise. This limitation could thus be more problematic over a longer time period where the magnitude of these societal changes could be expected to be much greater.
In this analysis, we estimated the cost of scaling up selected interventions in 68 countries. At an additional cost of US$0.80 per person per year, we can achieve nearly universal coverage of many key diarrhea prevention and treatment interventions. With additional investments in water and sanitation by households and the public sector we could ensure nearly every young child has access to safe water. We did not calculate costs per life saved because this analysis presents only the diarrheal deaths averted and thus fails to capture the full impact. Many of the diarrhea interventions avert deaths from other causes, either directly though prevention of pneumonia (e.g. breastfeeding) or indirectly via a reduction in diarrhea incidence (e.g. hygiene promotion) and stunting and thus the diarrheal deaths averted, which are presented here, likely underestimate the total deaths averted when scaling up this package of interventions.
It was beyond the scope of this analysis and costing exercise to fully estimate the costs required to adequately strengthen the health system in 68 diverse countries to sustainably maintain these high coverage levels. Furthermore, evidence suggests that cost curves are complex and nonlinear for infrastructure, commodities management, transportation, performance monitoring, and supervision [24]. We recognize that ensuring coverage in geographically or socially underserved communities may require strategies or delivery channels that are more costly than those needed to reach more accessible populations and, thus, generalizing per capita expenses where both disease burden and access to the health system vary has its limitations [25],[26]. Additional studies to explore variations in costing strategies are needed and may produce results that are more tailored to specific countries and populations.
To ensure the high coverage rates proposed here are achievable, new resources are needed to strengthen health systems for delivery of services, and to support the introduction and scale-up of recently introduced interventions for diarrhea treatment (low osmolarity ORS and zinc) and prevention (rotavirus vaccine) [27]. It is recognized that intense promotion of ORS use at the community level, and training of health workers during the WHO program for the control of diarrheal disease in the 1980s, was successful in scaling up coverage and reducing diarrheal deaths, although progress stagnated during the 1990s [3],[28]. There is evidence that promotion of zinc for diarrhea treatment alongside ORS can increase uptake and use, reduce unnecessary antibiotic use, and reinvigorate community management of diarrhea [29],[30]. However, there are a number of potential obstacles related to financing, national policy formulation, training, service delivery, and demand creation that are currently limiting scale-up of these strategies and that require urgent attention.
Real progress can be made if the prevention and treatment of diarrhea becomes an international priority and the global health community commits to a number of key actions as laid out in the 2009 UNICEF and WHO report [3]: mobilizing dedicated and sufficient funding for diarrhea control; leveraging global partnerships and networks for strong and effective advocacy; establishing clear and targeted health promotion and behavior change communication strategies; expanding the reach of health services into communities to ensure that diarrhea prevention and treatment is a central component of a “revitalized” community-based primary health care approach; and undertaking complementary efforts across both public and private sectors to promote innovations in supply and delivery of these key interventions to reach high and equitable coverage. In addition, because increasing coverage of these interventions requires input and leadership from multiple sectors and ministries within government, coordination will be critical to ensure success. lf the bottlenecks can be overcome and the international community can collectively deliver on the key actions noted above, then child morbidity and mortality due to diarrhea can be dramatically reduced and contribute to the achievement of MDG4. These analyses remind us that reaching goals in reducing under-five mortality does not require the development of new technologies or interventions; rather, these can be reached by implementing existing low cost and effective interventions.
Supporting Information
Zdroje
1. Black
RE
Cousens
S
Johnson
HL
Lawn
JE
Rudan
I
2010
Global, regional, and national causes of child mortality in 2008: a
systematic analysis.
Lancet
375
1969
1987
2. Snyder
JD
Merson
MH
1982
The magnitude of the global problem of acute diarrhoeal disease: a
review of active surveillance data.
Bull World Health Organ
60
605
613
3. UNICEFWHO
2009
Diarrhoea: why children are still dying and what can be
done.
Geneva
WHO
4. Stover
J
McKinnon
R
Winfrey
B
2010
Spectrum: a model platform for linking of maternal and child survival
interventions with AIDS, family planning and demographic
projections.
Int J Epi
39
i7
i10
5. UNICEF
2008
Tracking progress in maternal, newborn and child
survival.
New York
UNICEF
6. Walker
N
Fischer Walker
CL
Bryce
JL
Bahl
R
Cousens
S
2010
Standards for CHERG Reviews of Intervention Effects on Child
Survival.
Int J Epi
39
i21
i31
7. Cairncross
S
Hunt
C
Boisson
S
Bostoen
K
Curtis
V
2010
Water, sanitation, and hygiene for the prevention of
diarrhoea.
Int J Epi
39
i193
i205
8. Fischer Walker
CL
Black
RE
2010
Zinc for the treatment of diarrhoea: effect on diarrhoea morbidity,
mortality and incidence of future episodes.
Int J Epi
39
i63
i69
9. Munos
MK
Fischer Walker
CL
Black
RE
2010
The effect of oral rehydration solution and recommended home fluids on
diarrhoea mortality.
Int J Epi
39
i75
i87
10. Munos
MK
Fischer Walker
CL
Black
RE
2010
The effect of rotavirus vaccine on diarrhoea
mortality.
Int J Epi
39
i56
i62
11. Traa
BS
Fischer Walker
CL
Munos
M
Black
RE
2010
Antibiotics for the treatment of dysentery in
children.
Int J Epi
39
i70
i74
12. Bhutta
ZA
Ahmed
T
Black
RE
Cousens
S
Dewey
K
2008
What works? Interventions for maternal and child undernutrition
and survival.
Lancet
371
417
440
13. Black
RE
Allen
LH
Bhutta
ZA
Caulfield
LE
de Onis
M
2008
Maternal and child undernutrition: global and regional exposures and
health consequences.
Lancet
371
243
460
14. Friberg
IK
Bhutta
ZA
Darmstadt
GL
Bang
A
Cousens
S
2010
Neonatal: comparing modelled predictions of neonatal mortality impacts
using LiST with observed results of community-based intervention trials in South
Asia.
Int J Epi
39
i11
i20
15. Hazel
E
Gilroy
K
Friberg
I
Black
RE
Bryce
J
2010
ACSD: Comparing the modeled to the measured mortality reduction:
applying the Lives Saved Tool to evaluate data from the Accelerated Child Survival
Project in West Africa.
Int J Epi
30
i32
i39
16. Bryce
J
Boschi‐Pinto
C
Shibuya
K
2005
WHO estimates of the causes of death in children.
Lancet
365
1147
1152
17. Interagency Group for Child Mortality Estimation
2009
Child mortality estimation.
Available: http://www.childmortality.org/cmeMain.html. Accessed 31 December
2009
18. World Health Organization
2010
Progress on sanitation and drinking water: 2010
update.
Geneva
WHO
19. WHO
2010
WHO/UNICEF estimates of national immunization
coverage.
Available: http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/index4.html.
Accessed 19 March 2010
20. Waddington
H
Snilstveit
B
White
H
Fewtrell
L
2009
Water, sanitation, and hygiene interventions to combat childhood
diarrhoea in developing countries in International Initiative for Impact
Evaluation. 3rd edition.
London
Intiative for Impact Evaluation
21. UNICEF
2010
Supply catalogue.
Available: http://www.supply.unicef.dk/catalogue/. Accessed 1 September
2010
22. WHO
2010
Tables of costs and prices used in WHO-CHOICE
analysis.
Available: http://www.who.int/choice/costs/en/. Accessed 1 September
2010
23. Boerma
JT
Bryce
J
Kinfu
Y
Axelson
H
Victora
CG
2008
Mind the gap: equity and trends in coverage of maternal, newborn, and
child health services in 54 Countdown countries.
Lancet
371
1259
1267
24. Johns
B
Baltussen
R
2004
Accounting for the cost of scaling-up health
interventions.
Health Econ
13
1117
1124
25. Johns
B
Torres
TT
2005
Costs of scaling up health interventions: a systematic
review.
Health Policy Plan
20
1
13
26. Guinness
L
Kumaranayake
L
Hanson
K
2007
A cost function for HIV prevention services: is there a
‘u’ - shape?
Cost Eff Resour Alloc
5
13
27. Santosham
M
Chandran
A
Fitzwater
S
Fischer-Walker
C
Baqui
AH
Black
R
2010
Progress and barriers for the control of diarrhoeal
disease.
Lancet
376
63
67
28. Victora
CG
Bryce
J
Fontaine
O
Monasch
R
2000
Reducing deaths from diarrhoea through oral rehydration
therapy.
Bull World Health Organ
78
1246
1255
29. Baqui
AH
Black
RE
Arifeen
SE
Yunus
M
Chakraborty
J
2002
Effect of zinc supplementation started during diarrhoea on morbidity
and mortality in Bangladeshi children: community randomised trial.
BMJ
325
1059
30. Bhandari
N
Mazumder
S
Taneja
S
Dube
B
Agarwal
RC
2008
Effectiveness of zinc supplementation plus oral rehydration salts
compared with oral rehydration salts alone as a treatment for acute diarrhea in a
primary care setting: a cluster randomized trial.
Pediatrics
121
1279
1285
31. Curtis
VA
Danquah
LO
Aunger
RV
2009
Planned, motivated and habitual hygiene behaviour: an eleven country
review.
Health Education Review
24
655
673
32. WHO
WHO/UNICEF estimates of national immunization
coverage.
Available: http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/index4.html.
Accessed 19 March 2010
Štítky
Interní lékařstvíČlánek vyšel v časopise
PLOS Medicine
2011 Číslo 3
- Co lze v terapii hypertenze očekávat od přidání perindoprilu k bisoprololu?
- Příznivý vliv Armolipidu Plus na hladinu cholesterolu a zánětlivé parametry u pacientů s chronickým subklinickým zánětem
- Berberin: přírodní hypolipidemikum se slibnými výsledky
- Léčba bolesti u seniorů
- Flexofytol® – přírodní revoluce v boji proti osteoartróze kloubů
Nejčtenější v tomto čísle
- The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices
- How Can Institutional Review Boards Best Interpret Preclinical Data?
- The Challenge of Discharging Research Ethics Duties in Resource-Constrained Settings
- HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis